Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOUT-HCM: Mavacamten in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2023-505650-17-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Hypertrophic Obstructive Cardiomyopathy (HOCM) comparing Mavacamten with Placebo (2 arms). Primary endpoint: Change from baseline in Valsalva LVOT gradient at Week 28. Planned start Apr 2024; status: authorised.
02
Drugs
mavacamten
03
Conditions
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on 2023-505650-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505650-17-00.